Global cancer in women: Burden and trends

Cancer Epidemiology Biomarkers and Prevention

Volumn 26, Issue 4, 2017, Pages 444-457

  Torre, Lindsey A ^a   Islami, Farhad ^a   Siegel, Rebecca L ^a   Ward, Elizabeth M ^a   Jemal, Ahmedin ^a  

^a AMERICAN CANCER SOCIETY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER CONTROL; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SURVIVOR; CAUSE OF DEATH; COLORECTAL CANCER; DEVELOPED COUNTRY; ECONOMIC DEVELOPMENT; FEMALE; HIGHEST INCOME GROUP; HUMAN; LIVER CANCER; LOW INCOME COUNTRY; LUNG CANCER; MALAWI; MIDDLE INCOME COUNTRY; OVARY CANCER; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THYROID CANCER; TREND STUDY; UTERINE CERVIX CANCER; UTERUS CANCER; ZIMBABWE; COLORECTAL TUMOR; FACTUAL DATABASE; FEMALE GENITAL TRACT TUMOR; GLOBAL HEALTH; INCIDENCE; LIVER TUMOR; LUNG TUMOR; MORTALITY; NEOPLASM; STATISTICS AND NUMERICAL DATA;

CAUSE OF DEATH; COLORECTAL NEOPLASMS; DATABASES, FACTUAL; FEMALE; GENITAL NEOPLASMS, FEMALE; GLOBAL HEALTH; HUMANS; INCIDENCE; LIVER NEOPLASMS; LUNG NEOPLASMS; NEOPLASMS; RISK FACTORS;

EID: 85016948083     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-16-0858     Document Type: Review

References (180)

1. United Nations Population Division. World Population Prospects, the 2015 revision. [cited 2016 October 14]. Available from: https://esa. un. org/unpd/wpp/.
2. Franceschi S, Wild CP. Meeting the global demands of epidemiologic transition-The indispensable role of cancer prevention. Mol Oncol 2013;7:1-13.
3. World Health Organization. Women and health: today's evidence, tomorrow's agenda. Geneva, Switzerland: World Health Organization; 2009.
4. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1. 0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. [cited 2015 July 30]. Available from: http://globocan. iarc. f.r.
5. Bray F, Ferlay J, Laversanne M, Brewster DH,Gombe Mbalawa C, Kohler B, et al. Cancer incidence in five continents: inclusion criteria, highlights from Volume X and the global status of cancer registration. Int J Cancer 2015;137:2060-71.
6. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. , editors. SEER Cancer Statistics Review, 1975-2011. Bethesda, MD: NCI; 2014. Available from: http://seer. cancer. gov/csr/1975-2011/.
7. Engholm G, Ferlay J, Christensen N, Kejs AMT, Johannesen TB, Khan S, et al. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 7. 1 (09. 07. 2015). Copenhagen, Denmark: Association of the Nordic Cancer Registries. Danish Cancer Society; 2015. Available from: http://www. ancr. n.u.
8. World Health Organization. Cancer Mortality Database. Lyon, France: International Agency for Research on Cancer; 2013[cited 2013 Dec 13]. Available from: http://www-dep. iarc. fr/WHOdb/WHOdb. htm.
9. Doll R, Cook P. Summarizing indices for comparison of cancer incidence data. Int J Cancer 1967;2:269-79.
10. Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med 2016;375:614-7.
11. Bradbury AR, Olopade OI. Genetic susceptibility to breast cancer. Rev Endocr Metab Disord 2007;8:255-67.
12. Colditz GA, Bohlke K. Priorities for the primary prevention of breast cancer. CA Cancer J Clin 2014;64:186-94.
13. Carter BD, Abnet CC, Feskanich D, Freedman ND, Hartge P, Lewis CE, et al. Smoking and mortality-beyond established causes. N Engl J Med 2015;372:631-40.
14. Ordonez-Mena JM, Schottker B, Mons U, Jenab M, Freisling H, Bueno-de-Mesquita B, et al. Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium. BMC Med 2016;14:62.
15. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 2002; 360:187-95.
16. Islami F, Liu Y, Jemal A, Zhou J,Weiderpass E, Colditz G, et al. Breastfeeding and breast cancer risk by receptor status-a systematic reviewandmetaanalysis. Ann Oncol 2015;26:2398-407.
17. Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA. Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol 2005;34:405-12.
18. Colditz GA, Sellers TA, Trapido E. Epidemiology-identifying the causes and preventability of cancer? Nat Rev Cancer 2006;6:75-83.
19. Youlden DR, Cramb SM, Dunn NA, Muller JM, Pyke CM, Baade PD. The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol 2012;36:237-48.
20. Autier P, Boniol M, Gavin A, Vatten LJ. Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ 2011;343:d4411.
21. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353:1784-92.
22. Bosetti C, Bertuccio P, Levi F, Chatenoud L, Negri E, La Vecchia C. The decline in breast cancer mortality in Europe: an update (to 2009). Breast 2012;21:77-82.
23. Chatenoud L, Bertuccio P, Bosetti C, Malvezzi M, Levi F, Negri E, et al. Trends in mortality frommajor cancers in the Americas: 1980-2010. Ann Oncol 2014;25:1843-53.
24. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to theHumanDevelopment Index (2008-2030): a populationbased study. Lancet Oncol 2012;13:790-801.
25. Youlden DR, Cramb SM, Yip CH, Baade PD. Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol Med 2014; 11:101-15.
26. Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, EzzatiM, Comparative Risk Assessment Collaborating group. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 2005;366:1784-93.
27. Lauby-Secretan B, Scoccianti C, Loomis D, Benbrahim-Tallaa L, Bouvard V, Bianchini F, et al. Breast-Cancer Screening-Viewpoint of the IARC Working Group. N Engl J Med 2015;372:2353-8.
28. International Agency for Research on Cancer. IARC handbooks of cancer prevention-Vol. 15: Breast cancer screening. Lyon, France: IARC Press; 2015.
29. Anderson BO, Ilbawi AM, El Saghir NS. Breast cancer in low and middle income countries (LMICs): a shifting tide in global health. Breast J 2015;21:111-8.
30. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 2012;367:1998-2005.
31. Prasad V, Lenzer J, Newman DH. Why cancer screening has never been shown to save lives-and what we can do about it. BMJ 2016;352:h6080.
32. Sankaranarayanan R. Screening for cancer in low-and middle-income countries. Ann Glob Health 2014;80:412-7.
33. Zelle SG, Nyarko KM, Bosu WK, Aikins M, Niens LM, Lauer JA, et al. Costs, effects and cost-effectiveness of breast cancer control in Ghana. TropMed Int Health 2012;17:1031-43.
34. Devi BC, Tang TS, Corbex M. Reducing by half the percentage of latestage presentation for breast and cervix cancer over 4 years: a pilot study of clinical downstaging in Sarawak, Malaysia. Ann Oncol 2007; 18:1172-6.
35. Sankaranarayanan R, Ramadas K, Thara S, Muwonge R, Prabhakar J, Augustine P, et al. Clinical breast examination: preliminary results from a cluster randomized controlled trial in India. J Natl Cancer Inst 2011; 103:1476-80.
36. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015;385:977-1010.
37. Ganz PA, Yip CH, Gralow JR, Distelhorst SR, Albain KS, Andersen BL, et al. Supportive care after curative treatment for breast cancer (survivorship care): resource allocations in low-and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. Breast 2013;22:606-15.
38. Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst 2012;104: 386-405.
39. Pinto AC, de Azambuja E. Improving quality of life after breast cancer: dealing with symptoms. Maturitas 2011;70:343-8.
40. Villain P, Gonzalez P, Almonte M, Franceschi S, Dillner J, Anttila A, et al. European code against cancer 4th edition: infections and cancer. Cancer Epidemiol 2015;39Suppl 1:S120-S138.
41. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens-Part B: biological agents. Lancet Oncol 2009;10:321-2.
42. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011;128:927-35.
43. de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007;7:453-9.
44. Shvetsov YB, Hernandez BY, McDuffie K, Wilkens LR, Zhu X, Ning L, et al. Duration and clearance of anal human papillomavirus (HPV) infection among women: the Hawaii HPV cohort study. Clin Infect Dis 2009; 48:536-46.
45. Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT, et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 2012;30Suppl 5:F24-33.
46. Martin-Hirsch PL, Wood NJ. Cervical cancer. BMJ Clin Evid 2011;2011: pii:0818.
47. Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet 2013;382:889-99.
48. De Vuyst H, Alemany L, Lacey C, Chibwesha CJ, Sahasrabuddhe V, Banura C, et al. The burden of human papillomavirus infections and related diseases in sub-Saharan Africa. Vaccine 2013;31Suppl 5:F32-46.
49. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical humanpapillomavirusprevalence in5continents:meta-analysisof1million women with normal cytological findings. J Infect Dis 2010;202:1789-99.
50. FormanD, deMartel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012;30Suppl 5:F12-23.
51. Vaccarella S, Lortet-Tieulent J, Plummer M, Franceschi S, Bray F. Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur J Cancer 2013;49:3262-73.
52. Bray F, Lortet-Tieulent J, Znaor A, Brotons M, Poljak M, ArbynM. Patterns and trends in human papillomavirus-related diseases in Central and Eastern Europe and Central Asia. Vaccine 2013;31Suppl 7:H32-45.
53. Chokunonga E, Borok MZ, Chirenje ZM, Nyakabau AM, Parkin DM. Trends in the incidence of cancer in the black population of Harare, Zimbabwe 1991-2010. Int J Cancer 2013;133:721-9.
54. Wabinga HR, Parkin DM, Wabwire-Mangen F, Nambooze S. Trends in cancer incidence in Kyadondo County, Uganda, 1960-1997. Br J Cancer 2000;82:1585-92.
55. Committee on Adenloscent Health Care Immunization Expert Work Group. Committee opinion no. 641: human papillomavirus vaccination. Obstet Gynecol 2015;126:e38-43.
56. World Health Organization. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec 2014;89:465-91.
57. Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agents Cancer 2012;7:38.
58. Campos NG, Castle PE, Wright TC Jr, Kim JJ. Cervical cancer screening in low-resource settings: a cost-effectiveness framework for valuing tradeoffs between test performance and program coverage. Int J Cancer 2015; 137:2208-19.
59. Alliance for Cervical Cancer Prevention. Pap smears: an important but imperfect screening method. Lyon, France: International Agency for Research on Cancer; 2002. Available from: http://screening. iarc. fr/doc/ RH-pap-smears. pdf.
60. World Health Organization. WHOguidelines for screening and treatment of precancerous lesions for cervical cancer prevention. South Africa: World Health Organization; 2013.
61. Fokom-Domgue J, Combescure C, Fokom-Defo V, Tebeu PM, Vassilakos P, Kengne AP, et al. Performance of alternative strategies for primary cervical cancer screening in sub-Saharan Africa: systematic review and meta-analysis of diagnostic test accuracy studies. BMJ 2015;351:h3084.
62. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, Salmeron J, Uribe P, Velasco-Mondragon E, et al. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet 2011;378:1868-73.
63. Catarino R, Petignat P, Dongui G, Vassilakos P. Cervical cancer screening in developing countries at a crossroad: Emerging technologies and policy choices. World J Clin Oncol 2015;6:281-90.
64. Toliman P, Badman SG, Gabuzzi J, Silim S, Forereme L, Kumbia A, et al. Field evaluation of the Xpert(R) HPV Point of Care Test for the detection of human papillomavirus infection using self-collected vaginal and clinician-collected cervical specimens. J Clin Microbiol 2016;54:1734-7.
65. Wright TC Jr, Kuhn L. Alternative approaches to cervical cancer screening for developing countries. Best Pract Res Clin Obstet Gynaecol 2012;26: 197-208.
66. Park SY, Bae DS, Nam JH, Park CT, Cho CH, Lee JM, et al. Quality of life and sexual problems in disease-free survivors of cervical cancer compared with the general population. Cancer 2007;110:2716-25.
67. Frumovitz M, Sun CC, Schover LR, Munsell MF, Jhingran A, Wharton JT, et al. Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol 2005;23:7428-36.
68. Zeng YC, Li D, Loke AY. Life after cervical cancer: quality of life among Chinese women. Nurs Health Sci 2011;13:296-302.
69. Chaturvedi AK, Engels EA, Gilbert ES, Chen BE, Storm H, Lynch CF, et al. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst 2007;99:1634-43.
70. Suprasert P, Manopunya M. Financial burden of gynecologic-cancer survivors associated with attendance in a surveillance program at a tertiary care hospital in Thailand. Asian Pac J Cancer Prev 2011;12:1761-3.
71. Cook LS, Weiss NS, Doherty JA, Chen C. Endometrial cancer. In:Schottenfeld D, Fraumeni JF Jr, editors. Cancer epidemiology and prevention. 3rd ed. New York, NY: Oxford University Press; 2006.
72. Prat J, Franceschi S. Cancers of the female reproductive organs. In:Stewart BW, Wild CP, editors. World Cancer Report 2014. Lyon, France: International Agency for Research on Cancer; 2014.
73. Arnold M, Pandeya N, Byrnes G, Renehan AG, Stevens GA, Ezzati M, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol 2015;16:36-46.
74. Yang HP, Wentzensen N, Trabert B, Gierach GL, Felix AS, Gunter MJ, et al. Endometrial cancer risk factors by 2 main histologic subtypes: the NIH-AARP Diet and Health Study. Am J Epidemiol 2013;177: 142-51.
75. World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Report. Food, nutrition, physical activity, and the prevention of endometrial cancer. Washington, DC: American Institute for Cancer Research; 2013. Available from: http://www. dietandcan cerreport. org.
76. Al-Zoughool M, Dossus L, Kaaks R, Clavel-Chapelon F, Tjonneland A, Olsen A, et al. Risk of endometrial cancer in relationship to cigarette smoking: results from the EPIC study. Int J Cancer 2007; 121:2741-7.
77. National Center for Chronic Disease Prevention and Health Promotion Office on Smoking and Health. The health consequences of smoking-50 years of progress: a Report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention; 2014.
78. ArnoldM, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. Eur J Cancer 2015;51:1164-87.
79. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
80. Lee JY, Kim EY, Jung KW, Shin A, Chan KK, Aoki D, et al. Trends in gynecologic cancer mortality in East Asian regions. J Gynecol Oncol 2014;25:174-82.
81. Weiderpass E, Antoine J, Bray FI, Oh JK, Arbyn M. Trends in corpus uteri cancer mortality in member states of the European Union. Eur J Cancer 2014;50:1675-84.
82. Puschel K, Sullivan S, Montero J, Thompson B, Diaz A. [Cost-effectiveness analysis of a preventive program for gallbladder disease in Chile]. Rev Med Chil 2002;130:447-59.
83. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol 2014;15:23-34.
84. El Mistiri M, Salati M, Marcheselli L, Attia A, Habil S, Alhomri F, et al. Cancer incidence, mortality, and survival in Eastern Libya: updated report from the Benghazi Cancer Registry. Ann Epidemiol 2015;25:564-8.
85. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet 2009; 374:1371-82.
86. Hunn J, Rodriguez GC. Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol 2012;55:3-23.
87. Collaborative Group On Epidemiological Studies Of Ovarian Cancer, Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, et al. Menopausal hormone use and ovarian cancer risk: individual participant metaanalysis of 52 epidemiological studies. Lancet 2015;385:1835-42.
88. World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Report. Food, nutrition, physical activity, and the prevention of ovarian cancer 2014. Washington, DC: American Institute for Cancer Research; 2014. Available from: http://www. dietand cancerreport. org/cup/cup-resources. php.
89. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls. Lancet 2008;371:303-14.
90. Secretan B, Straif K, Baan R, Grosse Y, El Ghissassi F, Bouvard V, et al. A review of human carcinogens-Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 2009;10:1033-4.
91. Malvezzi M, Carioli G, Rodriguez T, Negri E, La Vecchia C. Global trends and predictions in ovarian cancermortality. Ann Oncol 2016;27:2017-25.
92. Bray F, Loos AH, Tognazzo S, La Vecchia C. Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000. Int J Cancer 2005;113:977-90.
93. Havrilesky LJ, Gierisch JM, Moorman PG, Coeytaux RR, Peragallo Urrutia R, Lowery WJ, et al. Oral contraceptive use for the primary prevention of ovarian cancer. Evidence Report/Technology Assessment No. 212. Rockville, MD: Agency for Healthcare Research and Quality; 2013.
94. Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 2016;387:945-56.
95. Pinsky PF, Yu K, Kramer BS, Black A, Buys SS, Partridge E, et al. Extended mortality results for ovarian cancer screening in the PLCO trial with median 15 years follow-up. Gynecol Oncol 2016;143:270-5.
96. Maringe C, Walters S, Butler J, Coleman MP, Hacker N, Hanna L, et al. Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership. Gynecol Oncol 2012;127: 75-82.
97. Bouvard V, Loomis D, Guyton KZ, Grosse Y, Ghissassi FE, Benbrahim-Tallaa L, et al. Carcinogenicity of consumption of red and processed meat. Lancet Oncol 2015;16:1599-600.
98. Fedewa SA, Sauer AG, Siegel RL, Jemal A. Prevalence of major risk factors and use of screening tests for cancer in the United States. Cancer Epidemiol Biomarkers Prev 2015;24:637-52.
99. Tao S, Hoffmeister M, Brenner H. Development and validation of a scoring system to identify individuals at high risk for advanced colorectal neoplasms who should undergo colonoscopy screening. Clin Gastroenterol Hepatol 2014;12:478-85.
100. World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Report Summary. Food, nutrition, physical activity, and the prevention of colorectal cancer. Washington, DC: American Institute for Cancer Research; 2011.
101. Murphy G, Devesa SS, Cross AJ, Inskip PD, McGlynn KA, Cook MB. Sex disparities in colorectal cancer incidence by anatomic subsite, race and age. Int J Cancer 2011;128:1668-75.
102. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-78.
103. Song M, Hu FB, Spiegelman D, Chan AT, Wu K, Ogino S, et al. Adulthood weight change and risk of colorectal cancer in the Nurses' Health Study and Health Professionals Follow-up Study. Cancer Prev Res 2015;8:620-7.
104. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut 2016. doi: 10. 1136/gutjnl-2015-310912.
105. Zauber AG, Winawer SJ, O'Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, et al. Colonoscopic polypectomy and longterm prevention of colorectal-cancer deaths. N Engl J Med 2012;366: 687-96.
106. Brenner H, Chang-Claude J, Rickert A, Seiler CM, Hoffmeister M. Risk of colorectal cancer after detection and removal of adenomas at colonoscopy: population-based case-control study. J Clin Oncol 2012; 30:2969-76.
107. Corley DA, Jensen CD, Marks AR, Zhao WK, Lee JK, Doubeni CA, et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med 2014;370:1298-306.
108. Loberg M, Kalager M, Holme O, Hoff G, Adami HO, Bretthauer M. Longterm colorectal-cancer mortality after adenoma removal. N Engl J Med 2014;371:799-807.
109. Strum WB. Colorectal adenomas. N Engl J Med 2016;374:1065-75.
110. Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, et al. Multitarget stool DNA testing for colorectal-cancer screening. NEngl J Med 2014;370:1287-97
111. Sali L, MascalchiM, FalchiniM, Ventura L, Carozzi F, Castiglione G, et al. Reduced and full-preparation CT colonography, fecal immunochemical test, and colonoscopy for population screening of colorectal cancer: a randomized trial. J Natl Cancer Inst 2016;108:pii:djv319.
112. Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JJ, Young GP, et al. Colorectal cancer screening: a global overview of existing programmes. Gut 2015;64:1637-49.
113. Khuhaprema T, Sangrajrang S, Lalitwongsa S, Chokvanitphong V, Raunroadroong T, Ratanachu-Ek T, et al. Organised colorectal cancer screening in Lampang Province, Thailand: preliminary results from a pilot implementation programme. BMJ Open 2014;4:e003671.
114. Allemani C, Rachet B, Weir HK, Richardson LC, Lepage C, Faivre J, et al. Colorectal cancer survival in the USA and Europe: a CONCORD highresolution study. BMJ Open 2013;3:e003055.
115. McArdle CS, McMillan DC, Hole DJ. Male gender adversely affects survival following surgery for colorectal cancer. Br J Surg 2003;90:711-5.
116. McCormack V, Lortet-Tieulent J, Shin HR, Bray F. Cancer in women: Global burden and insights from gender comparisons. In: Goldman MB, Troisi R, Rexrode KM, editors. Waltham, MA: Women and Health, Second Edition: Elsevier; 2013.
117. Maringe C, Walters S, Rachet B, Butler J, Fields T, Finan P, et al. Stage at diagnosis and colorectal cancer survival in six high-income countries: a population-based study of patients diagnosed during 2000-2007. Acta Oncol 2013;52:919-32.
118. Mariotto AB, Rowland JH, Ries LA, Scoppa S, Feuer EJ. Multiple cancer prevalence: a growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev 2007;16:566-71.
119. World Health Organization. WHO Global Report: Mortality Attributable to Tobacco 2012. Geneva, Switzerland: World Health Organization; 2012.
120. Oberg M, Jaakkola MS, Woodward A, Peruga A, Pruss-Ustun A. Worldwide burden of disease from exposure to second-hand smoke: a retrospective analysis of data from 192 countries. Lancet 2011; 377:139-46.
121. Gordon SB, Bruce NG, Grigg J, Hibberd PL, Kurmi OP, Lam KB, et al. Respiratory risks from household air pollution in low and middle income countries. Lancet Respir Med 2014;2:823-60.
122. Raspanti GA, Hashibe M, Siwakoti B, Wei M, Thakur BK, Pun CB, et al. Household air pollution and lung cancer risk among never-smokers in Nepal. Environ Res 2016;147:141-5.
123. Sisti J, Boffetta P. What proportion of lung cancer in never-smokers can be attributed to known risk factors? Int J Cancer 2012;131:265-75.
124. Hashim D, Boffetta P. Occupational and environmental exposures and cancers in developing countries. Ann Glob Health 2014;80:393-411.
125. HosgoodHDiII, Wei H, Sapkota A, Choudhury I, Bruce N, Smith KR, et al. Household coal use and lung cancer: systematic reviewand meta-analysis of case-control studies, with an emphasis on geographic variation. Int J Epidemiol 2011;40:719-28.
126. MuL, Liu L, Niu R, Zhao B, Shi J, Li Y, et al. Indoor air pollution and risk of lung cancer among Chinese female non-smokers. Cancer Causes Control 2013;24:439-50.
127. Hamra GB, Guha N, Cohen A, Laden F, Raaschou-Nielsen O, Samet JM, et al. Outdoor particulate matter exposure and lung cancer: a systematic review and meta-analysis. Environ Health Perspect 2014;122:906-11.
128. Baan R, Grosse Y, Straif K, Secretan B, El Ghissassi F, Bouvard V, et al. A review of human carcinogens-Part F: chemical agents and related occupations. Lancet Oncol 2009;10:1143-4.
129. Straif K, Benbrahim-Tallaa L, Baan R, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens-part C: metals, arsenic, dusts, and fibres. Lancet Oncol 2009;10:453-4.
130. El Ghissassi F, Baan R, Straif K, Grosse Y, Secretan B, Bouvard V, et al. A review of human carcinogens-part D: radiation. Lancet Oncol 2009;10: 751-2.
131. Freedman ND, Leitzmann MF, Hollenbeck AR, Schatzkin A, Abnet CC. Cigarette smoking and subsequent risk of lung cancer inmen and women: analysis of a prospective cohort study. Lancet Oncol 2008;9:649-56.
132. Thun M, Peto R, Boreham J, Lopez AD. Stages of the cigarette epidemic on entering its second century. Tob Control 2012;21:96-101.
133. Lopez AD, Collishaw NE, Piha T. A descriptive model of the cigarette epidemic in developed countries. Tob Control 1994;3:242-7.
134. Torre LA, Siegel RL, Ward EM, Jemal A. International variation in lung cancer mortality rates and trends among women. Cancer Epidemiol Biomarkers Prev 2014;23:1025-36.
135. Islami F, Stoklosa M, Drope J, Jemal A. Global and regional patterns of tobacco smoking and tobacco control policies. Eur Urol Focus 2015:3-16.
136. Thun M, Nilson J, Liber A, Blecher E. The global tobacco epidemic. In: Stewart B, Wild C, editors. World Cancer Report 2014. Lyon, France: International Agency for Research on Cancer; 2014.
137. Holford TR, Meza R, Warner KE, Meernik C, Jeon J, Moolgavkar SH, et al. Tobacco control and the reduction in smoking-related premature deaths in the United States, 1964-2012. JAMA 2014;311:164-71.
138. WarrenCW, Lea V, Lee J, JonesNR, AsmaS,McKenna M. Change in tobacco use among 13-15 year olds between 1999 and 2008: findings from the Global Youth Tobacco Survey. Glob Health Promot 2009;16:38-90.
139. Islami F, Torre LA, Jemal A. Global trends of lung cancer mortality and smoking prevalence. Transl Lung Cancer Res 2015;4:327-38.
140. Pirie K, Peto R, Reeves GK, Green J, Beral V, Million Women Study C. The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK. Lancet 2013; 381:133-41.
141. Thun MJ, Carter BD, Feskanich D, Freedman ND, Prentice R, Lopez AD, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med 2013;368:351-64.
142. National Lung Screening Trial Research T, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with lowdose computed tomographic screening. NEngl JMed2011;365:395-409.
143. Optican RJ, Chiles C. Implementing lung cancer screening in the real world: opportunity, challenges and solutions. Transl Lung Cancer Res 2015;4:353-64.
144. Smith RA, Andrews K, Brooks D, DeSantis CE, Fedewa SA, Lortet-Tieulent J, et al. Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2016;66:95-114.
145. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2013, based on November 2015 SEER data submission, posted to the SEER web site. Bethesda, MD: NCI; 2016.
146. Zeng H, Zheng R, Guo Y, Zhang S, Zou X, Wang N, et al. Cancer survival in China, 2003-2005: a population-based study. Int J Cancer 2015;136: 1921-30.
147. Sarna L, Evangelista L, Tashkin D, Padilla G, Holmes C, Brecht ML, et al. Impact of respiratory symptoms and pulmonary function on quality of life of long-term survivors of non-small cell lung cancer. Chest 2004; 125:439-45.
148. Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health 2016;4:e609-616.
149. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015;386: 1546-55.
150. Hadziyannis SJ. Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. J Hepatol 2011;55:183-91.
151. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-42.
152. World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva, Switzerland: WHO Press; 2014.
153. Puri P, Anand AC, Saraswat VA, Acharya SK, Dhiman RK, Aggarwal R, et al. Consensus statement of HCV task force of the Indian National Association for Study of the Liver (INASL). Part I: Status Report of HCVInfection in India. J Clin Exp Hepatol 2014;4:106-16.
154. McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis 2015;19:223-38.
155. Thiese ND. Liver Cancer. In:Stewart BW, Wild CP, editors. World Cancer Report 2014. Lyon, France: International Agency for Research on Cancer; 2014.
156. Cabibbo G, Maida M, Genco C, Antonucci M, Camma C. Causes of and prevention strategies for hepatocellular carcinoma. Semin Oncol 2012; 39:374-83.
157. Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, et al. Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer 2016;122:1312-37.
158. BosettiC, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol 2014;28:753-70.
159. Gibb H, Devleesschauwer B, Bolger PM, Wu F, Ezendam J, Cliff J, et al. World Health Organization estimates of the global and regional disease burden of four foodborne chemical toxins, 2010: a data synthesis. F1000Res 2015;4:1393.
160. Liu Y, Chang CC, Marsh GM, Wu F. Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. Eur J Cancer 2012;48:2125-36.
161. Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang YY, et al. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci 2010;101:579-85.
162. Tanaka H, Imai Y, Hiramatsu N, Ito Y, Imanaka K, Oshita M, et al. Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. Ann Intern Med 2008;148:820-6.
163. TanakaM, Katayama F, Kato H, TanakaH, Wang J,Qiao YL, et al. Hepatitis B andCvirus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol 2011;21:401-16.
164. Chiang CJ, Yang YW, You SL, LaiMS, Chen CJ. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA 2013; 310:974-6.
165. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91.
166. Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 2013;47Suppl:S2-6.
167. Qu C, Chen T, Fan C, Zhan Q, Wang Y, Lu J, et al. Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial. PLoS Med 2014;11:e1001774.
168. World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva, Switzerland: WHO Press; 2015.
169. Islami F, Dikshit R,Mallath MK, Jemal A. Primary liver cancer deaths and related years of life lost attributable to hepatitis B and C viruses in India. Cancer Epidemiol 2016;40:79-86.
170. Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA 2014;312:631-40.
171. Arama V, Leblebicioglu H, Simon K, Zarski JP, Niederau C, Habersetzer F, et al. Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies. Antivir Ther 2014;19:245-57.
172. Jayasekera CR, Barry M, Roberts LR, Nguyen MH. Treating hepatitis C in lower-income countries. N Engl J Med 2014;370:1869-71.
173. Solomon SS, Mehta SH, Srikrishnan AK, Solomon S, McFall AM, Laeyendecker O, et al. Burden of hepatitis Cvirus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study. Lancet Infect Dis 2015;15:36-45.
174. Yilmaz H, Yilmaz EM, Leblebicioglu H. Barriers to access to hepatitis C treatment. J Infect Dev Ctries 2016;10:308-16.
175. Ditah I, Al Bawardy B, Gonzalez HC, Saberi B, Ditah C, Kamath PS, et al. Lack of health insurance limits the benefits of hepatitis C virus screening: insights from the NationalHealth and Nutrition ExaminationHepatitis C follow-up study. Am J Gastroenterol 2015;110:1126-33.
176. Rein DB, Wittenborn JS, Smith BD, Liffmann DK, Ward JW. The costeffectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. Clin Infect Dis 2015;61:157-68.
177. Duangsong R, Promthet S, Thaewnongiew K. Development of a community-based approach to opisthorchiasis control. Asian Pac J Cancer Prev 2013;14:7039-43.
178. Sithithaworn P, Yongvanit P, Duenngai K, Kiatsopit N, Pairojkul C. Roles of liver fluke infection as risk factor for cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2014;21:301-8.
179. Jemal A, Vineis P, Bray F, Torre L, Forman D, editors. The Cancer Atlas. 2nd ed. Atlanta, GA: American Cancer Society; 2014.
180. Ezzati M, Friedman AB, Kulkarni SC, Murray CJ. The reversal of fortunes: trends in county mortality and cross-county mortality disparities in the United States. PLoS Med 2008;5:e66.